Fig. 1

Absolute benefit and risks of SGLT-2 inhibition for people with CKD with and without diabetes, estimated from 13 large randomised clinical trials of SGLT-2 inhibition (adapted from [4]). CKD – chronic kidney disease. eGFR – estimated glomerular filtration rate. SE – standard error. SGLT-2i – sodium-glucose co-transporter 2 inhibitor. Figure licensed under Creative Commons CC-BY license